Akèy › Paragangliom
Etid klinik pou Paragangliom ap rekrite nan Etazini
14 etid pou Paragangliom ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Sep 29, 2026 · NCT06479811Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04924075Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Aug 25, 2026 · NCT03206060Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Aug 18, 2026 · NCT06427798Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06377033Familial Investigations of Childhood Cancer Predisposition
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 17, 2026 · NCT03050268A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Jun 15, 2026 · NCT06041516Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT0728258718F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou May 19, 2026 · NCT06503146Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou May 14, 2026 · NCT05636618Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Mar 17, 2026 · NCT04119024In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Feb 27, 2026 · NCT0563654068-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Ap rekriteFaz 4
Laj 18 a 100 · Tout sèks · Mizajou Nov 21, 2025 · NCT04081701Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Oct 15, 2025 · NCT03160274Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.